Assistant Professor, Medicine, UCLA School of Medicine
Hematology
Dr. Edward B. Garon, MD
|
|
Give Review
Edward Garon practices Hematology. He graduated from Washington University School of Medicine in St. Louis. Dr. Edward B. Garon is also a published MD. He has 43 paper published. The most recent paper is: Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small c... Edward B. Garon, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
- Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small c...
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung Cancer.
- Patient Portal Preferences: Perspectives on Imaging Information.
- Representing and extracting lung Cancer study metadata: Study objective and study design.
- Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung Cancer patient who progressed on crizotinib with diffuse leptomeninge...
- Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizum...
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Pa...
- Using multiplexed assays of oncogenic drivers in lung Cancers to select targeted drugs.
- PGE2-Driven Expression of c-Myc and OncomiR-17-92 Contributes to Apoptosis Resistance in NSCLC.
- Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung Cancer.
- PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carbo...
- Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung Cancer.
- The role of estrogen, progesterone and aromatase in human non-small-cell lung Cancer.
- Targeting MEK for the Treatment of Non-Small-Cell Lung Cancer.
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic c...
- Uncertainty and psychological adjustment in patients with lung Cancer.
- A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer After Dis...
- Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung Cancer.
- Development of transcriptomic biomarker signature in human saliva to detect lung Cancer.
- Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung Cancer.
- Proteomic analysis of human saliva from lung Cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry.
- Mitotic inhibitors.
- 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib.
- The new staging system for lung Cancer: imaging and clinical implications.
- Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid Tumors.
- Poly(ADP-ribose) polymerase inhibitors.
- Novel drugs--miscellaneous category.
- Proapoptotic agents in lung Cancer.
- Management of small-cell lung Cancer: time to move forward.
- Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast Cancer and non-small cell lung...
- Intracellular signaling molecules.
- In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies.
- High prevalence of lung Cancer in a surgical cohort of lung Cancer patients a decade after smoking cessation.
- Salivary diagnostics.
- Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.
- Inflammation and Lung carcinogenesis: applying findings in prevention and treatment.
- Nanoelectropulse intracellular perturbation and electropermeabilization technology: phospholipid translocation, calcium bursts, chromatin rearrangement, cardiomyocyte ...
- Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells.
- Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticoBiliary...
- Progesterone and estrogen receptor expression and activity in human non-small cell lung Cancer.
Schools
Washington Univ Sch Of Med
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
UCLA Medical Center -
University of Chicago -
Washington University School of Medicine in St. Louis
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1134153745 | |
| NPPES Provider LastName | GARON | |
| NPPES Provider FirstName | EDWARD | |
| NPPES Provider ZIPCode | 900950001 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 99.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134153745 |
| Last Name Of The Provider | GARON |
| First Name Of The Provider | EDWARD |
| View All |
Similar Doctors
|
Dr. Jason S. Ho, MD |
|
|
Dr. Michelle Afkhami, MD |
|
|
Dr. Maria M. Brenneisen, MD |
|
|
Dr. Andrea A. D'Auria, DO |
|
|
Dr. Fariborz Mortazavi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dinesh Rao, MD |
|
|
Dr. Eddie Thara, DO |
|
|
Dr. David D. Chang, MD |
|
|
Dr. Jennifer L. Gansert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angelique E. Richardson, MD |
|
|
Dr. Giridharan Ramsingh, MD
This Doctor is OpenDoctor Recommended.
|